State of the art chemotherapeutic management of pediatric brain tumors

被引:7
作者
Siegel, Melissa J. [1 ]
Finlay, Jonathan L. [1 ]
Zacharoulis, Stergios [1 ]
机构
[1] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Neural Tumors Program, Los Angeles, CA 90027 USA
关键词
angiogenesis inhibitors; biological modifiers; chemotherapy management; ependymoma; high-grade glioma; immunotherapy; low-grade glioma; medulloblastoma; pediatric brain tumors; recurrent tumors;
D O I
10.1586/14737175.6.5.765
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
CNS tumors are the most common solid tumor of childhood. This article will review current treatments for pediatric brain tumors; low-grade gliomas, high-grade gliomas, medulloblastomas and ependymomas. It will also highlight the treatments that are used for brain tumors in very young children and in children with recurrent brain tumors. The management of recurrent pediatric brain tumors unresponsive to standard therapy will be discussed. The agents used in this setting are mainly biological modifiers, which attempt to provide molecularly targeted therapy. Future directions of therapy for pediatric brain tumors are described. Future treatment paradigms will need to consider examining the use of multiple biological modifiers. Similarly, these agents will need to be examined in combination with cytotoxic chemotherapy. Finally, the future direction of pediatric neuro-oncology and the focus of the field as it battles pediatric brain tumors is discussed.
引用
收藏
页码:765 / 779
页数:15
相关论文
共 174 条
[1]   Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma [J].
Alsina, M ;
Fonseca, R ;
Wilson, EF ;
Belle, AN ;
Gerbino, E ;
Price-Troska, T ;
Overton, RM ;
Ahmann, G ;
Bruzek, LM ;
Adjei, AA ;
Kaufmann, SH ;
Wright, JJ ;
Sullivan, D ;
Djulbegovic, B ;
Cantor, AB ;
Greipp, PR ;
Dalton, WS ;
Sebti, SM .
BLOOD, 2004, 103 (09) :3271-3277
[2]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[3]  
[Anonymous], 1996, CANC EPIDEMIOLOGY PR
[4]  
ARENSON E, 1999, J PEDIAT HEMATOL ONC, V21, P325
[5]   Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience [J].
Barlogie, B .
SEMINARS IN HEMATOLOGY, 2003, 40 (04) :33-38
[6]   Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers [J].
Bartlett, JB ;
Michael, A ;
Clarke, IA ;
Dredge, K ;
Nicholson, S ;
Kristeleit, H ;
Polychronis, A ;
Pandha, H ;
Muller, GW ;
Stirling, DI ;
Zeldis, J ;
Dalgleish, AG .
BRITISH JOURNAL OF CANCER, 2004, 90 (05) :955-961
[7]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[8]   Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas [J].
Black, P ;
Carroll, R ;
Glowacka, D .
PEDIATRIC NEUROSURGERY, 1996, 24 (02) :74-78
[9]   Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: A pediatric brain tumor consortium study (PBTC-001) [J].
Blaney, SM ;
Boyett, J ;
Friedman, H ;
Gajjar, A ;
Geyer, R ;
Horowtiz, M ;
Hunt, D ;
Kieran, M ;
Kun, L ;
Packer, R ;
Phillips, P ;
Pollack, IF ;
Prados, M ;
Heideman, R .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :525-531
[10]   Epidemiologic impact of children with brain tumors [J].
Bleyer, WA .
CHILDS NERVOUS SYSTEM, 1999, 15 (11-12) :758-763